Medications to Treat Addiction - Masspartnership · 2017. 11. 4. · 1. Addiction is a complex but...
Transcript of Medications to Treat Addiction - Masspartnership · 2017. 11. 4. · 1. Addiction is a complex but...
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
Institute for Behavioral HealthSCHNEIDER INSTITUTES FOR HEALTH POLICY
MedicationstoTreatAddiction
SharonReif,Ph.D.
Improving Quality and Integration of Substance Use Disorder Treatment in the Era of Accountable CareMBHP/MassHealth Provider Conference -- November 7, 2017
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Colleagues– ConnieHorgan;DeborahGarnick,AndreaAcevedo,CathyFullerton;CindyParksThomas;MaureenStewart,TimCreedon,Ann-MarieMatteucci,DominicHodgkin
• Brandeis-HarvardNIDACentertoImproveSystemPerformanceofSubstanceUseDisorderTreatment
• Noconflictsofinterest
Acknowledgments
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Settingthestage• Pharmacotherapy• Barriers• Effectiveness• Opportunitiesforimprovement
Today’spresentation
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
SETTINGTHESTAGE
(twitter 10/30/2017)
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
Identify
Treat
AbstinenceRecovery
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
Cascadeofcare
POPULATION
DIAGNOSEDwithSUD
LINKTOCARE
INITIATEMAT(orEBP)
RETENTION
ContinuousAbstinenceRecovery
38% initiation rate for all SUD, Medicaid2
11% engagement rate, Medicaid2
18% with SUD access any treatment1
7.5% have SUD1
1 NSDUH 2016; 2 MBHP IET website, national averages
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
1. Addictionisacomplexbuttreatablediseasethataffectsbrainfunctionandbehavior
2. Nosingletreatmentisappropriateforeveryone3. Treatmentneedstobereadilyavailable4. Effectivetreatmentattendstomultipleneeds,notjustSUD5. Remainingintreatmentforadequatetimeiscritical6. Behavioraltherapiesaremostcommonlyused7. Medicationsareanimportantelement,especially
combinedwithbehavioraltherapies
Principlesofeffectivetreatment
NIDA Principles of Drug Abuse Treatment, 3rd edition, 2012
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
PHARMACOTHERAPY(MEDICATION-ASSISTEDTREATMENT)
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Medicationsto:– stoporreducesubstanceuse– reducecraving
• FDA-approvedmedicationsavailableforalcohol,opioids– naloxone≠ treatment
• Psychosocialtreatmentrecommendedinconjunction– yetfindingsaremixed,especiallyforopioidusedisorders
• Responsemightvaryacrosspatientsub-groups
• EndorsedbyNQF,NIDA,ASAM,meta-analyses,manyresearchstudies• Treatmentguidelinesexist(seeresourcesatend)
Pharmacotherapy/MAT
NIDA Principles of Effective Treatment: Medications are an important element, especially combined with behavioral therapies
1st Consensus Standard for SUD Treatment: Pharmacotherapy (for withdrawal and for dependence)
ASAMPublicPolicyStatement,OUDNationalPracticeGuidelines:PharmacologicaltherapycanbeapartofeffectiveprofessionaltreatmentforOUD…bestaccompaniedbyandprovidedinconjunctionwithevidence-basedpsychosocialtreatmentsandrecoverysupportinterventions
Medications Development: Treatment for alcohol use disorder includes behavioral treatments…as well as pharmaceutical treatments
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Pharmacotherapyforaddictionhasevolvedsignificantly– typesofmedications,modesofadministration
• Improvedacceptabilityandaccess– specialtysettingsthattraditionallyusedanabstinence-basedapproachareincreasinglyusingmedicationstotreataddictions
– buprenorphineandothermedicationsavailablewithinoffice-basedsettings– lessrelianceonopioidtreatmentprograms(OTPs)– medicationsbeyondmethadoneavailableinOTPs– roleforprimarycare,psychiatry,communityhealthcenters,etc.
Changingenvironment
Reif et al., 2017, JSAT
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
UNDER-UTILIZED
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Smallproportionareprescribedaddictionmeds• e.g.<2.5%ofalcohol-dependentpatientsintheVAreceivedaprescriptionfororalnaltrexoneorothermedicationforalcoholdependence
• <33%ofclinicallyappropriatepatientsreceivedprescriptionsinspecialtytreatmentprogramsthatprescribeanyaddictionmeds
• Prescribingforaddictionismuchlesscommonthanformentaldisorders• e.g.70%ofthosewithpsychiatricdiagnosesreceivedpsychiatricprescriptionsinthesamespecialtyprograms
Fewwhowouldbenefitreceiveprescriptions
as cited in Reif et al. 2017, JSAT
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• <50%ofspecialtytreatmentprogramsprescribedanyaddictionmeds1– Buprenorphineprescribedin58%OTPsand21%non-OTPs2
– Injectablenaltrexoneprescribedin23%OTPsand16%non-OTPs2
• Mostbuprenorphineprescriberspracticewellundertheircurrentpatientlimitandhavenumerousmonthswithnopatientepisodes3– Buprenorphineprescriberstreated13patientspermonth,onaverage,withamedianofonly4patientspermonth
– Evenprescriberswiththe100+patientwaivertreatedonlyabout33patientspermonth,onaverage,medianof23
Limitedprescribingbythosewhocoulddoso
1 as cited in Reif et al. 2017, JSAT; 2 SAMHSA CBHSQ Report 2017; 3 Thomas et al. 2017, DAD – 3 state study
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
BARRIERS…
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Complexclients• Training• Implementation• Fidelity• Clinicalinertia• Lackofmedicalstaff• Researchtopracticedelay• Practicetoresearchgap• Reimbursement
Barrierstoadoptinganynewpractice
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Ambivalenceaboutgettingtreatment• Knowledge
– effectiveness,wheretogethelp• Stigma
– patient,family,providers– OTPdailyclinicattendanceandrequirementsreinforce“personwithSUD”
• Cost– prescriberswhodon’tacceptMedicaidorotherinsurance
• Availability– waiveredprescribers,prescribersacceptingnewpatients,geographicaccess
Patientbarriers
Reif et al. 2017, J Psychoactive Drugs; Reif et al. 2017, JSAT
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Knowledgeandtraining,confidence– effectiveness,appropriateness,induction,psychosocialsupports
• Structural– buprenorphinewaiverandprescribinglimits,lackofmedicalstaff,injectionorimplantrequirements
andcapability,storageofmedications,drugscreens,prescribingandpsychosocialsupportpartners• Practiceconstraints
– time,multipleprioritiesduringofficevisit,reimbursementissues– anti-medicationbias(philosophical/cultural)– worrythatwillbecomeinundatedwithmedicationrequests
• Diversionconcerns• Stigma
– amongproviders,mayalsolimitknowledge,screening,referraltotreatment• Notinterested
– addictionoverall,treatingaddictionpatients,increasingaddictionpatientload
Prescriberbarriers
Reif et al. 2017, J Psychoactive Drugs; Reif et al. 2017, JSAT
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
EFFECTIVENESS
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY http://addictionblog.org/infographics/medications-for-opiate-and-opioid-addiction/
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Disulfiram[Antabuse]• Naltrexone– oral1 [Revia]
– greatlyreducedriskofheavydrinkingcomparedtoplacebo– slightdecreaseindrinkingdays,heavydrinkingdays,amountofalcoholconsumed– reducescraving,betterthanacamprosate– effectonabstinencebestifabstinentbeforestartingnaltrexone
• Naltrexone– extendedreleaseinjectable2 [Vivitrol]– comparabletooralnaltrexonebutnotbetter– improvedadherence(long-actinginjection)
• Acamprosate3 [Campral]– greatlyreducedriskofanydrinkingcomparedtoplacebo– effectonabstinenceisbestifdetoxedbeforestartingacamprosate– noeffectonheavydrinking
AlcoholUseDisorders
1 Rosner et al. 2010a; Maisel et al. 2012; 2 Maisel et al. 2012; Gastfriend 2011; 3 Rosner et al. 2010b
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Methadone1– reducesillicitopioiduse– improvestreatmentretention– somepositiveeffectsonmortality,otherdruguse,HIVriskbehaviors,criminalactivity– responserelatedtodosage(60mgatminimum)
• Buprenorphinewithnaloxone2 [Suboxone]– effectscomparabletomethadone,withfewersideeffects
• Naltrexone– extendedreleaseinjectable3 [Vivitrol]– comparedtoplacebo,higherratesofabstinence,opioidfree-days,treatmentretention,
andlesscraving– aseffectiveasbuprenorphineforshort-termabstinence(long-termdatanotavailable)
OpioidUseDisorders
1 Fullerton et al. 2014; 2 Thomas et al. 2014; 3 Krupitsky et al. 2011; Gastfriend 2011; Tanum et al. 2017
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Somehaveimpliedthatmethadoneisnolongernecessary,butitisclearlystillthebesttreatmentforsome,especiallythosewithmoresevereOUDsorwhoareunsuccessfulinoffice-basedsettings
Reif et al. 2017, J Psychoactive Drugs; ASAM 2015; Knopf 2016; Mattick et al. 2014
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
READMISSIONSEXAMPLE
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• PeoplewithSUDshave– greatercomplexityofcare– morehospital-relatedcomplications– longerlengthsofstay– highercosts– highratesofreadmissions
• Promptreceiptoffollow-upSUDservicescouldreducereadmission– Outpatientservicesincommunitymentalhealthcenters(CMHC)reducereadmissionforMH/SUDpatients
– Follow-upservicespost-detoxreducedetoxreadmission
Background
Reif et al. 2017, Psychiatric Services
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Dotargetedfollow-upservicesreceivedshortlyafterdischargefrominpatienthospitalorresidentialdetoxificationreducelikelihoodofpost-dischargebehavioralhealthadmissionsamongMedicaidbeneficiarieswithanSUDdiagnosis
• Follow-upbehavioralhealthservicesinclude– Medication-assistedtreatment(MAT)
• definedasaprescriptionfillofbuprenorphine,disulfiram,acamprosate,ornaltrexoneoraHCPCSservicecodeformethadone,buprenorphine,ornaltrexone
– Outpatient(OP)– Intensiveoutpatientorpartialhospitalization(IOP)– Residential(RES)
Researchquestion
Reif et al. 2017, Psychiatric Services
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
Sample:• Medicaidenrollees(FFSonly),withanindexinpatientadmissionwithSUDdiagnosis(whetherornot
primary)• adults18-64• excludesdualMedicare/Medicaid• 2008claimsin10states– allofferedOPandMAT,5offeredIOP,3offeredRES
Outcome• timetoaBHadmissioninthe90daysfollowingdischargefromindexadmission
– inpatientadmissionwithanSUD/MHprimarydiagnosisOR– residentialdetoxificationadmission
Follow-upServices:MAT,OP,IOP,RES• receiptofeachserviceduring14-dayspost-discharge• #daystothefirstofanyofthefollow-upservicesreceivedwithin14-dayspost-discharge
Covariates:sociodemographics,SUDtype,comorbiddiagnoses,priorBHtreatment,indexLOS
Methods
Reif et al. 2017, Psychiatric Services
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
Example
InpatientDischarge
(Day 0)
14 days post-
discharge window
90 days post-discharge
MAT initiated Readmitted
Reif et al. 2017, Psychiatric Services
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
0
20
40
60
80
100
CT IL IN MN MO NC NY VT WV WI
%ofA
dmission
s
RES IOP OP NoRES,IOPorOPservice
KeyIndependentVariable:Follow-UpBHServicesin14DaysPost-Discharge
Reif et al. 2017, Psychiatric Services
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
0
20
40
60
80
100
CT IL IN MN MO NC NY VT WV WI
%ofA
dmission
s
MAT
KeyIndependentVariable:Follow-UpMATin14DaysPost-Discharge
Reif et al. 2017, Psychiatric Services
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
0
20
40
60
80
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
%ofA
dmission
s
DaysPost-Discharge
CT IL IN MN MO NC NY VT WV WI
KeyIndependentVariable:DaystoFirstBHFollow-UpService(OP,IOP,RES,MAT)
Reif et al. 2017, Psychiatric Services
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
Results:LikelihoodofBHinpatientadmission90dpost-dcg
• MATassociatedwith~40%reducedlikelihoodofBHinpatientadmission90dayspost-discharge– whencontrollingforotherfollow-upservicesreceived(OP,IOP,RES)– RESalsoassociatedwith~50%reducedlikelihood,butonlytestedin3states
– Controllingforstate,reasonforMedicaideligibilityandothercovariates
• Resultsconsistentwithotherstudies
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
OPPORTUNITIESFORIMPROVEMENT
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Traininginaddictionmedicinebroadlyandpharmacotherapy– confidenceassessingandacknowledgingaddiction,providingcaretopatientswithSUD– Increasedwillingnesstoprescribeanddevelopsupportsystemsforwhentheydoso– roleforprofessionalorganizations,healthplans,federalandstateagencies
• Disseminateguidelinesforuseofaddictionpharmacotherapy• Increasenumberofprescribers
– primarycareproviders,psychiatrists,addictionmedicine,others– nurses,physicianassistants– specialtytreatmentprogramswithtraditionalabstinence-basedapproach– roleforhealthplans,
SAMHSA,otherstoencourageandsupporttransition• Assistinidentifyingpsychosocialservicesandrecoverysupports
– Developcommunitypartnersandinformationnetworks• Workwithexperts/championstosupportless-experiencedprescribers
Increasingprescribers
Reif et al. 2017, JSAT
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Performancemeasures,incentivestructures,recognitionprograms– emphasizepharmacotherapyasanevidence-basedpracticeandrewardquality
• Pharmaceuticalcompanyrole,similartootherareasofmedicine– educatingortrainingproviders,offeringassistancewithmedicationrequirements,
subsidizingcopaysformedications• Partnershipswithprimarycaresettings
– accesstomedicalcareforaddictiontreatmentprogramswithoutin-housemedicalresources
– “hubandspoke”asonemodel• Otherconditionsmightoffermodelsforchange
– depressionandHIV,asmedicalconditionswhosetreatmentwasoncehighlystigmatizedandrelegatedonlytospecialtyproviders
Encouraginguseofpharmacotherapy
as cited in Reif et al. 2017, JSAT
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
SUMMARY
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• Medicationstotreataddictionareeffectiveandcost-effective• Utilizationbypatients,prescribers,andaddictiontreatmentprogramsisincreasing,butthereisstillalongwaytogo
• Barriersarewide-ranging• Manyopportunitiestosurmountbarriersandincreasemedicationuse• BeachampionformedicationasEBP• Recoveryremainsthegoal
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
QUESTIONS?Thankyou!
Sharon Reif, PhD, [email protected] for Behavioral HealthHeller School for Social Policy and Management, Brandeis University
InstituteforBehavioralHealthSCHNEIDERINSTITUTESFORHEALTHPOLICY
• ASAMNationalPracticeGuidelinefortheUseofMedicationsintheTreatmentofAddictionInvolvingOpioidUse
• https://asam.org/resources/guidelines-and-consensus-documents/npg
• SAMHSATIP43- Medication-AssistedTreatmentForOpioidAddictioninOpioidTreatmentPrograms• https://store.samhsa.gov/shin/content//SMA12-4214/SMA12-4214.pdf
• SAMHSATIP49- IncorporatingAlcoholPharmacotherapiesIntoMedicalPractice• https://store.samhsa.gov/shin/content//SMA13-4380/SMA13-4380.pdf
• SAMHSA– PocketGuide:Medication-AssistedTreatmentofOpioidUseDisorder• https://store.samhsa.gov/shin/content/SMA16-4892PG/SMA16-4892PG.pdf
• NIAAAHelpingPatientsWhoDrinkTooMuch:AClinician'sGuide• https://www.niaaa.nih.gov/guide
• SAMHSA– MedicationfortheTreatmentofAlcoholUseDisorder:ABriefGuide• https://store.samhsa.gov/shin/content//SMA15-4907/SMA15-4907.pdf
Resources